A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over ...

On May 5, 2026, Embecta released its second quarter fiscal 2026 financial results, revealing that revenue had declined over 14%, largely due to weakness in its pen needle sales. Additionally, the ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMBECTA CORP. (EMBC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) investors of the ...

Embecta Corp., a company noted for its century-long history in insulin delivery, is transitioning to a broader medical supplies focus. On August 8, 2025, at 8:00 a.m. ET, the company will hold a ...

Welcome, ladies and gentlemen, to Embecta Corp.'s Fiscal Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and a replay will ...

Welcome, ladies and gentlemen, to the Fiscal Fourth Quarter and Full Year 2023 embecta Earnings Conference Call. at this time, all participants have been placed in a listen-only mode. Please note that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Embecta Corp. (EMBC) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.67 per share a year ago. These ...